Defying "the norm" and creating a path to a better future for patients.  


Dan Dempsey

Founder & CEO

Dan has experience managing therapeutic antibody projects from preclinical stage through clinical trials. He witnessed first-hand issues the surrounding conventional antivenom and decided to act.



Deepankar Roy, PhD

Co-Founder & COO

Deepankar has expertise in drug manufacturing, project management, and business development. Familiar with and connected to Indian market.

Alex Capovilla.jpg

Alex Capovilla, PhD

Co-Founder & CSO

Alex has an extensive background in recombinant antibody engineering complemented by a history of bringing drugs to market overseas. 

Investors & partners